Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05849857 | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries(MERLIN) | recruiting | Phase 2 | 80 | Oslo University HospitalOTHER | 2 | Nov 1, 2023 | clinicaltrials |
| NCT05328258 | Use of GnRHa During Chemotherapy for Fertility Protection(ProFertil) | recruiting | Phase 3 | 500 | Kenny Rodriguez-WallbergOTHER | 1 | Oct 27, 2023 |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05230680 | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | recruiting | Phase 1 / Phase 2 | 41 | Won Seog KimOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04349358 | FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)(MIM) | recruiting | N/A | 38 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06084962 | A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | recruiting | Phase 1 | 40 | He HuangOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04558931 | Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | recruiting | Phase 2 | 62 | Karolinska InstitutetOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06065852 | National Registry of Rare Kidney Diseases(RaDaR) | recruiting | — | 35,000 | UK Kidney AssociationOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05444712 | Transplantation After Complete Response In Patients With T-cell Lymphoma(TRANSCRIPT) | recruiting | N/A | 204 | Hospices Civils de LyonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05768529 | Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03127761 | Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma | recruiting | — | 544 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | recruiting | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05996367 | Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma | recruiting | N/A | 50 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05982223 | Integrative Medicine in Lymphoma Survivors | recruiting | N/A | 90 | Bnai Zion Medical CenterOTHER_GOV | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05968417 | Myeloma Novel Drug Discovery Ver 1.2(DISCO) | recruiting | — | 250 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05965115 | The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study(CHAPERONE) | recruiting | — | 10,000 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05967949 | A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. | recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970198 | Helical Tomotherapy in Multiple Myeloma | recruiting | N/A | 58 | Fuling ZhouOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05846750 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 59 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05948033 | CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05899621 | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | recruiting | — | 332 | Ruijin HospitalOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05846763 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study | recruiting | — | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05831865 | Frontline of ASCT in High-risk DLBCL(Essential) | recruiting | — | 175 | Peking University People's HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05840575 | Investigating Cognitive Impairment in Young Patients With Cancer Prospectively(MyBrain) | recruiting | — | 100 | Rigshospitalet, DenmarkOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04006561 | Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost | recruiting | — | 36 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05833893 | Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma | recruiting | Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04920617 | DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(VITALIZE) | recruiting | Phase 2 | 102 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 10 | Apr 7, 2023 | clinicaltrials |
| NCT05231135 | A Registry Study on HIV-related Lymphoma | recruiting | — | 300 | Rotkreuzklinikum München gGmbHOTHER | 4 | Apr 6, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04088422 | Cell Free DNA in Mature B-cell Lymphoma | recruiting | — | 320 | Ruijin HospitalOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | recruiting | Phase 1 | 24 | Ningbo No. 1 HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05594797 | Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM | recruiting | Phase 2 | 100 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 28 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 289 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05552937 | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | recruiting | Phase 2 | 50 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT04442412 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy(FIL_PREVID) | recruiting | Phase 3 | 430 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02859402 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT) | recruiting | Phase 2 | 34 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma | recruiting | — | 100 | Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03161223 | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | recruiting | Phase 1 / Phase 2 | 148 | University of VirginiaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05260619 | Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma(PCNSL-LEM) | recruiting | Phase 2 | 28 | Seoul National University Bundang HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 1, 2023source: clinicaltrials